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Abstract
Aims/hypothesis Bariatric surgery is an effective treatment
for severe obesity, as in addition to dramatic weight loss,
co-morbidities such as type 2 diabetes are frequently
resolved. Although altered gastrointestinal peptide hormone
secretion and its relationship with post-surgical improve-
ments in insulin sensitivity has been studied, much less is
known about long-term changes in pancreatic and adipose
tissue-derived hormones. Our objective was to conduct a
comprehensive longitudinal investigation of the endocrine
changes following Roux-en-Y gastric bypass surgery
(RYGBP), focusing on pancreatic and adipocyte hormones
and systemic markers of inflammation.
Methods Nineteen severely obese women (BMI 45.6±
1.6 kg/m2) were studied prior to RYGBP, and at 1, 3, 6,
and 12 months after RYGBP. Body composition was
assessed before surgery and at 1 and 12 months.
Results Pre-surgical adiposity was correlated with cir-
culating adipocyte hormones (leptin, visfatin) and inflam-
matory molecules (IL-6, high sensitivity C-reactive protein
[hsCRP], monocyte chemoattractant protein-1). As ex-
pected, RYGBP reduced fat mass and fasting insulin and
glucose concentrations. In addition, reductions of fasting
pancreatic polypeptide (PP) and glucagon concentrations
were observed at 1 and 3 months, respectively. In the
12 months following RYGBP, concentrations of most
adipocyte hormones (leptin, acylation-stimulating hormone
and visfatin, but not retinol-binding hormone-4) and
inflammatory molecules (IL-6, hsCRP and soluble intracel-
lular adhesion molecule-1) were significantly reduced.
Reductions of insulin resistance (measured by homeostasis
model assessment of insulin resistance) were independently
associated with changes of glucagon, visfatin and PP. Pre-
surgical HMW adiponectin concentrations independently
predicted losses of body weight and fat mass.
Conclusions/interpretation These results suggest that pan-
creatic and adipocyte hormones may contribute to the long-
term resolution of insulin resistance after RYGBP.
Keywords Clinical science . Cytokines . Gastro-entero
pancreatic factors . Human . Insulin sensitivity and
resistance . Other hormones . Other islet cells/hormones .
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Abbreviations
ASP acylation-stimulating protein
CRP C-reactive protein
GLP-1 glucagon-like peptide 1
HMW high molecular weight
HOMA-
IR
homeostasis model assessment of insulin re-
sistance
hsCRP high-sensitivity C-reactive protein
MCP-1 monocyte chemoattractant protein-1
PP polypeptide
RBP4 retinol-binding protein-4
RYGBP Roux-en-Y gastric bypass
sICAM-1 soluble intercellular adhesion molecule-1
Introduction
Bariatric surgery is the most effective method for producing
weight loss in patients with severe obesity (BMI>40 kg/
m2). In addition to weight loss, the co-morbidities of severe
obesity, particularly type 2 diabetes mellitus, insulin
resistance, hyperlipidaemia, sleep apnoea and hypertension
are frequently resolved following surgery [1]. Accordingly,
the number of bariatric surgical procedures performed in
the USA increased eightfold between 1998 and 2004 [2].
Similar increases have been reported in many other
countries [3].
There is considerable interest in the physiological
mechanisms by which bariatric surgery, in particular
Roux-en-Y gastric bypass (RYGBP), resolves the co-
morbidities of severe obesity, as understanding them could
lead to the development of new (non-surgical) therapeutic
strategies. Much of the research to date has focused on
gastrointestinal hormones, such as ghrelin, glucagon-like
peptide-1 (GLP-1) and peptide-YY, and their relationships
with the weight loss, reduction of appetite and improved
insulin sensitivity that follow RYGBP [4]. However,
concomitant changes in pancreatic (glucagon, pancreatic
polypeptide [PP] and amylin) and adipocyte-derived hor-
mones have not been as intensively investigated.
Over the last two decades, adipose tissue has been
recognised as an active source of hormones involved in
energy homeostasis and substrate metabolism [5]. Adipo-
cyte-derived hormones include leptin, adiponectin and
acylation-stimulating protein (ASP), as well as the more
recently identified visfatin (also known as PBEF/NAMPT)
[6]. With the exception of adiponectin, circulating concen-
trations of these hormones are usually increased in obesity
and insulin-resistant states, and decline during weight loss
[7]. A role for adipocyte-derived retinol-binding protein-4
(RBP4) in systemic insulin resistance has also been recently
proposed: in transgenic mice, adipose-specific GLUT4
knockout increased serum RBP4 concentrations, which in
turn led to insulin resistance by impairing skeletal muscle
insulin action and increasing hepatic glucose output [8].
Obesity is also characterised by the infiltration of
macrophages into adipose tissue, promoting a state of
chronic, low-grade inflammation [9]. Relative to lean,
healthy individuals, obesity is associated with elevated
concentrations of C-reactive protein (CRP) [10], IL-6 [11],
monocyte chemoattractant protein-1 (MCP-1) [12] and
soluble intercellular adhesion molecule-1 (sICAM-1) [13].
This inflammatory state is implicated in the development of
many complications of severe obesity, in particular,
atherosclerosis, insulin resistance and type 2 diabetes [14].
The objective of this study was to conduct a compre-
hensive longitudinal examination of the endocrine and
metabolic changes following RYGBP, focusing on pancre-
atic and adipocyte hormones as well as inflammatory
markers. Many previous studies of the endocrine effects
of bariatric surgery have either been cross-sectional in
design or have only examined a single time-point after
surgery. We have previously reported that concentrations of
high molecular weight (HMW) adiponectin increase fol-
lowing RYGBP, and that these increases were proportional
to relative improvements in insulin resistance [15]. We now
provide additional information pertaining to other adipo-
cyte-derived hormones (leptin, ASP, visfatin, RBP4),
inflammatory markers (IL-6, high-sensitivity CRP
[hsCRP]) and pancreatic hormones (proinsulin, glucagon,
PP and amylin) after RYGBP in these severely obese
individuals.
Methods
Subjects Nineteen severely obese women (aged 40.6±
1.8 years, mean±SEM) underwent RYGBP surgery per-
formed at the University of California, Davis Medical
Center, or at Mercy San Juan Hospital in Sacramento, CA,
USA. Although patients were encouraged to lose weight
prior to surgery, their weight had been stable for the
preceding 3 months. Fasting blood samples were collected
prior to surgery, and at 1, 3, 6 and 12 months post-
operatively. Body composition was assessed prior to
surgery and at 1 and 12 months. The experimental protocol
was approved by Institutional Review Board of UC Davis,
and all participants provided written informed consent for
participation in the study.
Anthropometric and biochemical measurements Weight,
height, and waist and hip circumferences were measured
using standard methods. Body composition was determined
by air-displacement plethysmography (BodPod, Life Meas-
urements, Concord, CA, USA).
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All biochemical measurements were performed on fasting
plasma samples, except measurements of RBP4 and visfatin,
which were performed on fasting serum samples. Insulin,
proinsulin, leptin, glucagon and cortisol were measured by
radioimmunoassay (Linco, St Charles, MO, USA). Plasma
glucose was measured with a YSI glucose analyser (Yellow
Springs, OH, USA). Homeostatic model assessment of insulin
resistance (HOMA-IR) was calculated as previously described
[16]. NEFA concentrations were measured with an enzymatic
assay (Waco Chemicals, Richmond, VA, USA). RBP4 was
measured by ELISA (Alpco, Salem, NH, USA). MCP-1 and
sICAM-1 were measured by ELISA, and IL-6 was measured
using a Quantikine HS ELISA (all from R&D Systems,
Minneapolis, MN, USA). ASP and amylin were measured by
ELISA (Linco). The amylin assay measured human amylin,
deaminated amylin, the 1–20 fragment of amylin, but not
reduced amylin. PP was measured by radioimmunoassay
(Alpco). CRP was measured with an Immulite analyser and
hsCRP reagents (Diagnostic Products, Los Angeles, CA,
USA). Visfatin was measured by ELISA (Adipogen, Seoul,
South Korea).
Statistical analysis Statistical analysis was performed using
GraphPad Prism v. 4 (San Diego, CA, USA) and JMP Start
Statistics (SAS, Cary, NC, USA). All continuous variables
were assessed for normality using the Kolmogorov–Smirnov
test. Comparisons between baseline and post-surgical values
were made with one-way repeated measures ANOVA or the
non-parametric Friedman test. Post-test comparisons were
made with Bonferroni’s multiple comparison test, with the
pre-surgical values used as the reference. For sICAM-1 and
MCP-1, comparisons between baseline and 12 months were
made using paired t tests. Relationships between continuous
variables were assessed by non-parametric Spearman rank
correlation. Multivariate analyses were performed using
forward stepwise multiple logistic regression, as described
earlier [15]. The two-sided level of significance was p<
0.05. All mean values are shown ±SEM.
Results
Baseline characteristics and changes of body weight and
body composition following RYGBP Body composition and
biochemical measurements in the 19 participants are shown
in Table 1. At 1, 3, 6 and 12 months after RYGBP, average
reductions in body weight were 10.3±0.4%, 17.8±1.0%,
24.7±1.0% and 31.9±1.5%, respectively. Weight loss was
predominantly due to changes in fat mass, which was
reduced by 11.7±0.8% (7.6±0.5 kg) at 1 month and 49.6±
2.5% (32.7±2.4 kg) at 12 months. This was accompanied
by a modest, but significant, decrease of fat-free mass: 8.7±
0.9% (5.4±0.4 kg) at 1 month and 15.2±2.9% (9.2±1.7 kg)
at 12 months. Waist circumference and WHR were
significantly reduced at 1 and 6 months, respectively.
Plasma glucose, HOMA-IR and pancreatic hormones Three
individuals presented with fasting hyperglycaemia (plasma
glucose≥7.0 mmol/l) and another three with impaired
fasting glucose (6.1–6.9 mmol/l) prior to surgery. After
RYGBP, plasma glucose and insulin concentrations de-
creased progressively over the next 12 months (Fig. 1a,b).
Table 1 Changes of body composition, hormones and markers of inflammation in severely obese women following RYGBP
Variable Pre-operative 1 month 3 months 6 months 12 months Overall p value
n 19 19 18 19 19 –
Body weight (kg) 126.4±3.6 113.4±3.3*** 107.2±4.4*** 95.4±3.3*** 85.9±2.8*** <0.0001
BMI (kg/m2) 45.6±1.6 41.0±1.5*** 38.8±2.1*** 34.5±1.5*** 30.8±1.0*** <0.0001
Fat mass (kg) 65.5±2.7 58.2±2.5** – – 32.9±1.8*** <0.0001
Fat-free mass (kg) 60.9±2.0 55.2±1.6*** – – 53.0±2.5*** <0.0001a
Waist circumference (cm) 130±2 119±3* 111±3*** 104±2*** 100±2*** <0.0001
WHR 0.95±0.03 0.90±0.02 0.89±0.02 0.87±0.02* 0.88±0.02** 0.046
HOMA-IR 7.4±1.0 4.0±0.5*** 3.1±0.3*** 2.6±0.2*** 2.3±0.2*** <0.0001
Proinsulin:insulin ratio (%) 16.7±1.6 15.6±1.7 16.4±1.3 16.2±1.3 15.1±1.1 0.59
NEFA (mmol/l) 0.28±0.03 0.37±0.04 0.26±0.03 0.23±0.04 0.20±0.02 <0.0001
Cortisol (nmol/l) 232±22 265±28 262±25 295±30 257±25 0.10a
IL-6 (pg/ml) 4.16±0.50 3.88±0.33 – – 2.11±0.20*** <0.0001a
hsCRP (mg/l) 12.6±2.1 9.5±1.4 7.4±2.0** 5.2±1.4*** 2.8±0.7*** <0.0001
sICAM-1 (ng/ml) 243±9 – – – 216±9* 0.011
MCP-1 (pg/ml) 163±8 – – – 161±8 0.81
Data are shown as mean±SEM. Comparisons between baseline and each time-point were made using repeated measures one-way ANOVA,
except where its non-parametric equivalent, the Friedman test was useda. Levels of significance at each time-point were calculated using
Bonferroni’s multiple comparison test.
*p<0.05, **p<0.01, ***p<0.0001
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After 1 month, fasting insulin concentrations had decreased
by 34±8%, and glucose levels were normalised in all
individuals. Accordingly, HOMA-IR was significantly re-
duced by 1 month and continued to decrease thereafter
(Table 1). Plasma proinsulin concentrations decreased in
parallel with changes of insulin (Fig. 1c), such that the
proinsulin/insulin ratio (a marker of pancreatic beta
cell dysfunction [17]) was unchanged following RYGBP
(Table 1). When stratified by the presence or absence of pre-
surgical hyperglycaemia, the proinsulin/insulin ratio did not
change significantly in either group (data not shown). This
contrasts with the reported improvement of dynamic beta
cell function (accompanied by a reduced proinsulin/insulin
ratio) in patients with weight loss induced by vertical gastric
banding and jejunoileal bypass [18].
Fasting glucagon, PP and amylin concentrations were
also measured. In these severely obese women, fasting
plasma glucagon concentrations at baseline (98±11 ng/l)
were twice as high as those we have previously reported in
normal weight and overweight women, using the same
assay [19, 20]. Glucagon concentrations decreased follow-
ing RYGBP, being reduced by 22±8% at 3 months, 26±5%
at 6 and, 31±4% at 12 months (Fig. 1d). Plasma PP
concentrations were significantly decreased at 1 (−27±
10%) and 12 months (−17±13%), but not at 3 or 6 months
(Fig. 1e). Amylin concentrations did not change after
RYGBP (Fig. 1f).
Adipocyte hormones and inflammatory molecules As
expected, leptin concentrations prior to surgery were
proportional to body weight, BMI and fat mass (data not
shown). Concentrations of other adipocyte hormones and
inflammatory markers (visfatin, IL-6, MCP-1 and hsCRP)
were also correlated with body adiposity, but not with
fasting insulin concentrations or HOMA-IR (Table 2).
Visfatin concentrations were also positively correlated with
fat-free mass. Concentrations of RBP4, ASP and sICAM-1
were not significantly associated with measures of body
composition or insulin resistance at baseline.
Concentrations of most adipocyte hormones decreased
significantly 1 month after RYGBP (Fig. 2). Reductions of
leptin (−36±3%), visfatin (−20±6%), RBP4 (−28±6%) and
ASP (−18±7%) were observed. At 12 months, similarly,
concentrations of leptin and visfatin were reduced by 64±
4% and 41±8%, respectively. However, concentrations of
ASP and RBP4 at twelve months were not statistically
different from pre-surgical values.
RYGBP also led to a progressive reduction of some, but
not all markers of inflammation (Table 1). IL-6 concen-
trations were unchanged at 1 month after RYGBP, but were
reduced by 43±7% at 12 months (p<0.001). hsCRP
concentrations were reduced by 46±7% and 74±7% at 3
and 12 months, respectively. Concentrations of sICAM-1
were reduced by 10±4% after 12 months, while MCP-1
concentrations did not change significantly (Table 1).
Fig. 1 Fasting plasma concentrations of glucose, insulin and other
pancreatic hormones following RYGBP. Differences between time-points
were determined by repeated measures one-way ANOVA. *p<0.05,
**p<0.01 and ***p<0.0001 relative to pre-surgical values
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At 12 months, the relationship between leptin concen-
trations and adiposity remained significant (data not
shown), while leptin concentrations were also positively
correlated with fasting insulin (r=0.55, p=0.015) and
HOMA-IR (r=0.48, p=0.039). IL-6 concentrations were
positively correlated with WHR, fasting insulin and
HOMA-IR, and sICAM-1 concentrations were negatively
correlated with fasting glucose.
Hormones independently associated with changes of body
weight and body composition In our previous report [15],
we found that changes of HMW adiponectin were associated
with the changes in fat mass (Δfat mass) in the 12 months
following RYGBP, independently of age and initial BMI.
Using this model, we found that Δfat mass was also related
to changes of leptin (model 1, Table 3). This model
accounted for 71% of the variance in Δfat mass.
We next tested which baseline variables were predictive of
Δfat mass. Of the hormones studied, only baseline HMW
adiponectin concentrations predicted Δfat mass, indepen-
dently of age and BMI at baseline (model 2, Table 3 and
Fig. 3a). Similar results were obtained when we examined
proportional changes of fat mass; however, the models
explained less of the overall variance (data not shown).
Variables related to the change of body weight over the
12 months (Δbody weight) were also studied. As for Δfat
mass, changes of both leptin and HMW adiponectin were
Fig. 2 Fasting plasma concentrations of adipocyte hormones following
RYGBP. Differences between time-points were determined by repeated
measures one-way ANOVA. *p<0.05, **p<0.01, and ***p<0.0001
relative to pre-surgical values
Table 2 Significant correlations between continuous variables at
baseline and at 12 months
Variable 1 Variable 2 r p value
Significant correlations at baseline
Visfatin Body weight 0.65 0.0028
Waist circumference 0.50 0.035
Fat-free mass 0.55 0.015
IL-6 Body weight 0.59 0.007
BMI 0.67 0.002
Fat mass 0.70 0.0009
hsCRP Body weight 0.55 0.015
Waist circumference 0.51 0.030
Fat mass 0.55 0.014
MCP-1 BMI 0.60 0.007
Significant correlations at 12 month follow-up
IL-6 WHR 0.48 0.036
Insulin 0.67 0.0017
HOMA-IR 0.59 0.0074
sICAM-1 Glucose −0.48 0.036
Before RYGBP and at 12 month follow-up, hormones and inflamma-
tory markers were tested for correlation with measures of body
composition (weight, BMI, fat mass, lean mass, waist circumference,
WHR), fasting glucose and insulin concentrations, and insulin
resistance (HOMA-IR) by non-parametric Spearman rank. The level
of significance was p<0.05
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independently associated with Δbody weight (model 3,
Table 3). ΔBody weight was also independently predicted
by baseline concentrations of HMW adiponectin (Fig. 3b),
hsCRP (Fig. 3c) and ghrelin (model 4, Table 3).
Changes of each of the hormones measured here were
also tested for association with the changes of fat-free mass
after surgery. None of these were correlated with Δfat-free
mass (data not shown).
Hormones independently associated with changes of fasting
insulin and HOMA-IR In all participants, changes of fasting
insulin concentrations between baseline and 12 months
(Δinsulin) were significantly and independently associated
with changes of visfatin (p=0.0069) (Fig. 3d), glucagon
(p=0.021) and PP (p=0.030; model 5, Table 3). This model
accounted for 47% of the variation in Δinsulin. Due to the
non-linear relationship between Δglucagon and Δinsulin,
the proportional (%) changes were examined and these
were significantly correlated (r=0.56, p=0.013; Fig. 3e).
Relationships between the changes of hormones and
changes of HOMA-IR over the 12 months were also
examined. Analyses were limited to participants in whom
HOMA-IR improved by >15% at 12 months after surgery
[15], which yielded 18 participants. As for Δinsulin, the
absolute changes of HOMA-IR over the 12 months were
associated with changes of glucagon and visfatin (model 6,
Table 3).
The final model (model 7, Table 3) examined relative
changes of HOMA-IR, to account for the substantial
absolute improvement of insulin sensitivity that occurred
in the patients with hyperglycaemia at baseline. As
previously described [15], the proportional improvement
in HOMA-IR (%ΔHOMA-IR) over the 12 months was
related to age, ΔNEFA (Fig. 3f) and ΔHMW adiponectin
(model 7, Table 3). In this model, the change of IL-6
concentrations also tended to be independently associated
with %ΔHOMA-IR (p=0.056; Fig. 3g). This model
explained 59% of the variation in %ΔHOMA-IR.
Discussion
This study investigated the longitudinal changes of
pancreatic and adipocyte hormones following RYGBP
in severely obese women. Markers of inflammation were
also examined. While previous studies have reported
changes of several of these variables following bariatric
surgery, we believe that this study is the first longitudinal
Table 3 Multivariate analyses of variables associated with RYGBP-induced changes of body weight, fat mass, fasting insulin and HOMA-IR
Model n Dependent variable Independent variable ß coefficient SE p value Model r2 (adj)
1 19 ΔFat mass (kg) Age 0.432 0.194 0.043 0.71
0–12 months Initial BMI −0.237 0.222 0.30
ΔLeptin 0.349 0.111 0.0070
ΔHMWAd −3.786 1.217 0.0077
2 19 ΔFat mass (kg) Age 0.287 0.219 0.21 0.49
0–12 months Initial BMI −0.728 0.246 0.0098
Baseline HMWAd −4.695 1.721 0.016
3 19 ΔWeight (kg) Age 0.357 0.235 0.15 0.64
0–12 months ΔLeptin 0.478 0.120 0.0012
ΔHMWAd −3.740 1.459 0.022
4 19 ΔWeight (kg) Age −0.070 0.246 0.78 0.58
0–12 months Baseline HMWAd −7.604 1.958 0.0017
Baseline hsCRP −0.628 0.229 0.016
Baseline ghrelin 0.082 0.038 0.047
5 19 ΔFasting insulin Age 0.601 1.789 0.74 0.47
0–12 months ΔVisfatin 7.429 2.348 0.0069
ΔGlucagon 0.846 0.325 0.021
ΔPP 2.273 0.938 0.030
6 18 ΔHOMA-IR Age −0.187 0.092 0.062 0.42
0–12 months ΔGlucagon 0.072 0.020 0.0031
ΔVisfatin 0.343 0.147 0.035
7 18 %ΔHOMA-IR Age 0.732 0.321 0.040 0.59
0–12 months ΔHMWAd −8.995 2.511 0.0033
ΔNEFA −76.77 21.547 0.0035
ΔIL-6 −2.391 1.139 0.056
Stepwise multiple logistic regression was performed using the least squares method, as described by Swarbrick et al. [15].
Ad, adiponectin; r2 (adj), adjusted proportion of the variance accounted for by the model
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examination to be comprehensive in scope, due to the
number of measurements performed and the frequency of
follow-up examinations. A further strength of the present
study was that changes of body composition were
assessed. Its main limitations were that the sample size
was limited to only 19 individuals, all of whom were
women, and that we were not able to study responses to a
standardised meal. It was also not possible to assess
insulin sensitivity by FSIVGTT or euglycaemic clamps in
this study.
Fig. 3 Significant independent predictors of absolute and proportional
changes of body weight, fat mass, fasting insulin concentrations and
HOMA-IR. a Baseline HMW adiponectin (Ad) concentrations
predicted Δfat mass, r=–0.50, p=0.016 (model 2, Table 3) and b
Δbody weight, r=–0.40, p=0.0017 (model 4). c Baseline hsCRP
concentrations were also associated with Δbody weight following
RYGBP, r=−0.55, p=0.016 (model 4). d ΔVisfatin and Δinsulin were
significantly correlated, r=0.39, p=0.0069 (model 5). e Proportional
changes of glucagon and insulin were positively correlated with each
other (r=0.56, p=0.013). Independent relationships between changes
of f NEFA (r=–0.48, p=0.0035) and g IL-6 (r=–0.44, p=0.056) with
the relative improvement of HOMA-IR were also observed
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The first important new finding was that the elevated
fasting plasma glucagon concentrations in these severely
obese participants were markedly reduced after RYGBP.
This observation may be of physiological significance, as
changes of fasting glucagon concentrations were signif-
icantly and independently associated with the changes of
fasting insulin at 12 months after surgery. This relation-
ship was present when proportional changes of glucagon
and insulin were examined. In multivariate analysis,
changes of glucagon concentrations were independently
related to the improvements of HOMA-IR following
RYGBP. Previous studies of fasting glucagon concen-
trations before and after RYGBP have reported no change
either at 12 weeks [21] or 6 to 9 months after surgery
[22]. This discrepancy may be due to the limited time
course of the former study; and in the second study, a
closer examination of the data actually suggests a 28%
reduction of ‘pancreatic’ glucagon levels in the six
patients in which both pre- and post-surgical samples
were measured.
Glucagon plays a key physiological role in the mainte-
nance of fasting and postprandial glucose concentrations by
stimulating hepatic glucose production (reviewed in Dun-
ning and Gerich [23]). Inappropriately elevated plasma
glucagon concentrations have been reported in humans with
diabetes [24]. Future studies employing more direct
methods for determining insulin sensitivity and hepatic
glucose production will be required to determine the
specific role of glucagon in the resolution of insulin
resistance after RYGBP.
Although we did not have an opportunity to examine
meal-induced gastrointestinal hormone responses in the
present study, there is a growing consensus that changes in
their secretion are likely to contribute to improvement of
insulin sensitivity after RYGBP, and may do so prior to
significant weight loss [25]. For example, postprandial
GLP-1 levels increase as early as 2 days after RYGBP [26];
and in addition to its potential effects to stimulate insulin
secretion, GLP-1 has actions to suppress endogenous
glucose production, promote glucose uptake, and impor-
tantly, to reduce glucagon secretion [27]. Interestingly, our
results suggest that the decrease in fasting glucagon
concentrations may be specific for RYGBP, as another
group has reported that they did not change in 13 patients
who lost 25% of body weight after vertical gastric banding
or jejunoileal bypass [18]. We did measure fasting total
GLP-1 concentrations in the present study; however, no
significant changes were observed (data not shown).
Nonetheless, it is likely that postprandial GLP-1 secretion
was increased, and it is possible that repeated intermittent
increases of GLP-1 in the postprandial period contributed to
a sustained decrease of alpha cell function and reduced
pancreatic glucagon release.
Reduced fasting PP concentrations were also observed
after RYGBP. While this has been reported in one study
[28], another reported no change of PP after surgery [22].
This discrepancy may be due to small sample sizes or
differences in surgical technique. PP is released from
pancreatic F cells in response to food intake, gastrointes-
tinal hormones and neuropeptides. Its most important
regulator, however, is cholinergic vagal stimulation. Con-
sequently, plasma PP concentrations are useful as a marker
of pancreatic parasympathetic activity [29]. Our results
suggest that this declines shortly after RYGBP, consistent
with reductions of insulin and glucagon, since the secretion
of these hormones is also regulated by the parasympathetic
input to the islet [30]. These results suggest at least a partial
loss of the vagal input to the pancreas following RYGBP.
The second major finding was that RYGBP reduced
concentrations of most of the adipocyte hormones and
inflammatory molecules studied: leptin, hsCRP, ASP, IL-6
and sICAM-1.
Visfatin is a secreted protein produced at high levels in
visceral fat, and its plasma concentration is correlated with
visceral adiposity [6]. Accordingly, plasma concentrations
of visfatin are higher in humans with metabolic syndrome
than in normal weight control individuals [31]. Visfatin was
initially reported to have insulin-mimetic and adipogenic
actions [6], but these results were not supported by a
follow-up study [32]. However, in addition to reduced
circulating visfatin concentrations, female mice heterozy-
gous for visfatin deficiency exhibit impaired glucose
tolerance, and islets isolated from these mice have reduced
glucose-stimulated insulin secretion [32]. To date, studies
examining changes in visfatin with weight loss have
reported conflicting results: one study reported decreased
visfatin following RYGBP [33], while a subsequent study
reported an increase [34]. These discrepancies may be
partially explained by the use of a C-terminal assay for
visfatin that has recently been shown to lack specificity
[35]. Employing an ELISA that instead detects full-length
visfatin [35], we found: (1) visfatin concentrations were
positively associated with body weight and waist circum-
ference prior to surgery; (2) visfatin decreased progressive-
ly after RYGBP; and (3) reductions of visfatin were
independently associated with the changes of fasting insulin
concentrations and HOMA-IR (Fig. 3d and Table 3). These
results are consistent with the hypothesis that visfatin is
over-produced in severe obesity, possibly to compensate for
insulin resistance by either increasing adipose mass or
augmenting glucose-stimulated insulin secretion. It follows
that the need for such a mechanism would be reduced in the
weight-reduced state.
The role of the pro-inflammatory cytokine IL-6 in the
insulin resistance associated with human obesity remains a
subject of debate, as it has been reported to exert some
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insulin-sensitising effects in both healthy human individu-
als and those with type 2 diabetes [36]. Nonetheless,
circulating IL-6 concentrations have been reported to be
two- to fourfold higher in obese, type 2 diabetic patients
than in normal weight individuals [37] and to decrease with
weight loss [38]. In the present study, there were strong
positive correlations between circulating IL-6 concentra-
tions and measures of body adiposity prior to RYGBP.
Furthermore, IL-6 concentrations were reduced by 43±7%
12 months after surgery. At this time, IL-6 concentrations
were positively correlated with central adiposity, fasting
insulin and HOMA-IR. Last, there was a trend (p=0.056)
for a relationship between the changes of IL-6 and the
relative improvement in HOMA-IR, independent of age and
changes of NEFA and HMW adiponectin (Table 3 and
Fig. 3g). As proposed previously [38], in obesity, adipose
tissue is likely to be a major contributor to elevated IL-6
concentrations, and the underlying stimulus for its produc-
tion is removed by weight loss. In the weight-reduced state,
subsequently, the relationship between IL-6 concentrations
and insulin resistance is re-established.
Changes in RBP4 were also examined in the present
study, at 1 and 12 months after RYGBP. Serum RBP4
concentrations are elevated in overweight/obese humans
and positively correlated with BMI and insulin resistance
[39]. In the present study, however, we found no evidence
linking RBP4 with RYGBP-induced improvements in
insulin sensitivity. Although RBP4 concentrations de-
creased by nearly 30% 1 month after surgery, at 12 months
there was no significant decrease relative to pre-surgical
levels, despite marked weight loss and improved insulin
resistance.
Studies of RBP4 concentrations during weight loss have
shown significant reductions occur with weight loss of
>5%. One study [40] reported that serum RBP4 concen-
trations in severely obese humans decreased by ∼26% at
6 months after gastric banding, when participants had lost
13% of their initial weight. In patients undergoing vertical
banded gastroplasty, a similar reduction of RBP4 concen-
trations (∼20% after 1 month) was reported, although it was
not stated how much weight the patients lost [41]. In
healthy, insulin-sensitive menopausal women, however,
weight loss of 5% over 13 weeks, achieved by exercise
and reduction of energy intake by 2,510 kJ/day (600 kcal/
day), did not change serum RBP4 concentrations, despite a
20% decrease of fasting insulin [42]. We also measured
RBP4 concentrations in 14 healthy women before and after
a 7 day period of energy restriction to 2,635 kJ/day
(630 kcal/day) [43], during which the women lost 4% of
their body weight and plasma insulin concentrations
decreased by 46%. There was no significant change of
fasting RBP4 concentrations (before, 46.2±5.9 mg/l; after,
40.9±4.9 mg/l; p=0.33).
Moreover, there is some evidence to suggest that weight
loss-mediated reductions in RBP4 concentrations may not
be sustained in the long-term (12 months). Similar results to
ours have been reported recently in a study of obese women
consuming a very low energy diet (3,350 kJ [800 kcal/day])
for 4 weeks: a ∼7% reduction in body weight was
associated with a 15–20% decrease in plasma RBP4
concentrations [44]. Interestingly, an additional 3% weight
loss in these patients, achieved by a low-energy diet for
8 weeks followed by a weight-maintaining diet for 12–
16 weeks, resulted in a modest increase of RBP4 concen-
trations, although they were still reduced compared with
initial levels. This and other evidence [45] suggests that
changes in RBP4 concentrations may be more indicative of
energy intake than changes in body weight per se. It should
also be noted that adipose tissue is not the sole source of
RBP4, as it is most highly produced in liver, with adipose
tissue levels being about 20% of hepatic levels [46].
Last, as we previously reported for total adiponectin
concentrations [7], pre-surgical concentrations of HMW
adiponectin independently predicted weight loss following
RYGBP, with higher concentrations associated with greater
weight loss. Pre-operative HMW adiponectin concentra-
tions also predicted loss of fat mass. Adiponectin stimulates
fatty acid oxidation in liver and skeletal muscle [47], so it is
reasonable to hypothesise that a higher initial concentration
could enhance fat oxidation during negative energy
balance; however, this hypothesis will need to be addressed
in future studies.
The present study was designed to be a comprehensive
investigation of the longitudinal endocrine and metabolic
changes following RYGBP in severely obese women, with
an emphasis on pancreatic and adipocyte hormones and
markers of inflammation. While the contribution of
gastrointestinal hormones to improvements of insulin
resistance after RYGBP has been more extensively studied,
the present findings suggest that hormones from the
pancreas (glucagon and PP in particular) and adipose tissue
(visfatin and HMW adiponectin) may contribute to the
resolution of insulin resistance in the long term. Future
studies, involving larger numbers of patients of both sexes
as well as mechanistic studies, will be required to fully
determine the contributions of each of these hormones.
Accordingly, appropriate enhancement or blocking of the
effects of specific hormones may lead to the development
of new, non-surgical approaches for medical management
of the co-morbidities associated with severe obesity.
Acknowledgements We acknowledge the expert technical assis-
tance of J. Graham and E. Nuñez. This study was supported by a grant
award from the University of California Davis Health Care Systems. It
was also supported by the UC Davis Clinical and Translational
Science Center (grant number UL1 RR024146) and from the National
Center for Research Resources (NCRR), a component of the National
Diabetologia (2008) 51:1901–1911 1909
Institutes of Health (NIH) and NIH Roadmap for Medical Research.
The content of this manuscript is solely the responsibility of the
authors and does not necessarily represent the official view of NCRR
or NIH. P. J. Havel’s laboratory receives research support from NIH
grants: HL-075675, AT-002599, AT-00293, and the American Diabe-
tes Association. M. M. Swarbrick is supported by a New Investigator
Award from NAASO, The Obesity Society.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
References
1. Buchwald H, Avidor Y, Braunwald E et al (2004) Bariatric
surgery: a systematic review and meta-analysis. JAMA 292:1724–
1737
2. Zhao Y, Encinosa W (2007) Agency for Healthcare Research and
Quality. Bariatric surgery utilization and outcomes in 1998 and
2004. Statistical Brief #23. Available from http://www.hcup-us.
ahrq.gov/reports/statbriefs/sb23.pdf, accessed 15 July 2008
3. Buchwald H, Williams SE (2004) Bariatric surgery worldwide
2003. Obes Surg 14:1157–1164
4. le Roux CW, Bloom SR (2005) Why do patients lose weight after
Roux-en-Y gastric bypass. J Clin Endocrinol Metab 90:591–592
5. Havel PJ (2004) Update on adipocyte hormones: regulation of
energy balance and carbohydrate/lipid metabolism. Diabetes 53
(Suppl 1):S143–S151
6. Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a
protein secreted by visceral fat that mimics the effects of insulin.
Science 307:426–430
7. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone
K (2003) Plasma acylation-stimulating protein, adiponectin,
leptin, and ghrelin before and after weight loss induced by gastric
bypass surgery in morbidly obese subjects. J Clin Endocrinol
Metab 88:1594–1602
8. Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding
protein 4 contributes to insulin resistance in obesity and type 2
diabetes. Nature 436:356–362
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante AW Jr (2003) Obesity is associated with macrophage
accumulation in adipose tissue. J Clin Invest 112:1796–1808
10. Hak AE, Stehouwer CD, Bots ML et al (1999) Associations of C-
reactive protein with measures of obesity, insulin resistance, and
subclinical atherosclerosis in healthy, middle-aged women. Arte-
rioscler Thromb Vasc Biol 19:1986–1991
11. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001)
Adipose tissue tumor necrosis factor and interleukin-6 expression
in human obesity and insulin resistance. Am J Physiol Endocrinol
Metab 280:E745–E751
12. Kim CS, Park HS, Kawada T et al (2006) Circulating levels of
MCP-1 and IL-8 are elevated in human obese subjects and
associated with obesity-related parameters. Int J Obes (Lond)
30:1347–1355
13. Ferri C, Desideri G, Valenti M et al (1999) Early upregulation of
endothelial adhesion molecules in obese hypertensive men.
Hypertension 34:568–573
14. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms
linking obesity with cardiovascular disease. Nature 444:875–880
15. Swarbrick MM, Austrheim-Smith IT, Stanhope KL et al (2006)
Circulating concentrations of high-molecular-weight adiponectin
are increased following Roux-en-Y gastric bypass surgery.
Diabetologia 49:2552–2558
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC (1985) Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma glucose
and insulin concentrations in man. Diabetologia 28:412–419
17. Saad MF, Kahn SE, Nelson RG et al (1990) Disproportionately
elevated proinsulin in Pima Indians with noninsulin-dependent
diabetes mellitus. J Clin Endocrinol Metab 70:1247–1253
18. Guldstrand M, Ahren B, Adamson U (2003) Improved beta-cell
function after standardized weight reduction in severely obese
subjects. Am J Physiol Endocrinol Metab 284:E557–E565
19. Havel PJ, Ahren B (1997) Activation of autonomic nerves and the
adrenal medulla contributes to increased glucagon secretion
during moderate insulin-induced hypoglycemia in women. Dia-
betes 46:801–807
20. Havel PJ, Townsend R, Chaump L, Teff K (1999) High-fat meals
reduce 24-h circulating leptin concentrations in women. Diabetes
48:334–341
21. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL
(2004) Hormonal changes after Roux-en Y gastric bypass for
morbid obesity and the control of type-II diabetes mellitus. Am
Surg 70:1–4 (discussion 4–5)
22. Meryn S, Stein D, Straus EW (1986) Fasting- and meal-stimulated
peptide hormone concentrations before and after gastric surgery
for morbid obesity. Metabolism 35:798–802
23. Dunning BE, Gerich JE (2007) The role of alpha-cell dysregula-
tion in fasting and postprandial hyperglycemia in type 2 diabetes
and therapeutic implications. Endocr Rev 28:253–283
24. Gastaldelli A, Baldi S, Pettiti M et al (2000) Influence of obesity
and type 2 diabetes on gluconeogenesis and glucose output in
humans: a quantitative study. Diabetes 49:1367–1373
25. Cummings DE, Overduin J, Foster-Schubert KE (2004) Gastric
bypass for obesity: mechanisms of weight loss and diabetes
resolution. J Clin Endocrinol Metab 89:2608–2615
26. le Roux CW, Welbourn R, Werling M et al (2007) Gut hormones
as mediators of appetite and weight loss after Roux-en-Y gastric
bypass. Ann Surg 246:780–785
27. Salehi M, Aulinger BA, D’Alessio DA (2008) Targeting b-cell
mass in type 2 diabetes: promise and limitations of new drugs
based on incretins. Endocr Rev 29:367–379 doi:10.1210/er.2007-
0031
28. Schrumpf E, Linnestad P, Nygaard K, Giercksky KE, Fausa O
(1981) Pancreatic polypeptide secretion before and after gastric
bypass surgery for morbid obesity. Scand J Gastroenterol
16:1009–1014
29. Schwartz TW (1983) Pancreatic polypeptide: a unique model for
vagal control of endocrine systems. J Auton Nerv Syst 9:99–111
30. Havel PJ, Taborsky GJ Jr (1989) The contribution of the
autonomic nervous system to changes of glucagon and insulin
secretion during hypoglycemic stress. Endocr Rev 10:332–350
31. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf
MS (2007) Increased plasma levels of visfatin/pre-B cell colony-
enhancing factor in obese and overweight patients with metabolic
syndrome. J Endocrinol Invest 30:323–326
32. Revollo JR, Korner A, Mills KF et al (2007) Nampt/PBEF/
Visfatin regulates insulin secretion in beta cells as a systemic
NAD biosynthetic enzyme. Cell Metab 6:363–375
33. Manco M, Fernandez-Real JM, Equitani F et al (2007) Effect of
massive weight loss on inflammatory adipocytokines and the
innate immune system in morbidly obese women. J Clin
Endocrinol Metab 92:483–490
34. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP,
Schernthaner G (2006) Increase in visfatin after weight loss
induced by gastroplastic surgery. Obesity (Silver Spring)
14:1886–1889
35. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W
(2007) Molecular characteristics of serum visfatin and differential
1910 Diabetologia (2008) 51:1901–1911
detection by immunoassays. J Clin Endocrinol Metab 92:4783–
4791
36. Pedersen BK, Febbraio MA (2007) Point: interleukin-6 does have
a beneficial role in insulin sensitivity and glucose homeostasis. J
Appl Physiol 102:814–816
37. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley
RE (2001) Circulating interleukin-6 in relation to adiposity, insulin
action, and insulin secretion. Obes Res 9:414–417
38. Bastard JP, Jardel C, Bruckert E et al (2000) Elevated levels of
interleukin 6 are reduced in serum and subcutaneous adipose
tissue of obese women after weight loss. J Clin Endocrinol Metab
85:3338–3342
39. Graham TE, Yang Q, Bluher M et al (2006) Retinol-binding
protein 4 and insulin resistance in lean, obese, and diabetic
subjects. N Engl J Med 354:2552–2563
40. Haider DG, Schindler K, Prager G et al (2007) Serum retinol-
binding protein 4 is reduced after weight loss in morbidly obese
subjects. J Clin Endocrinol Metab 92:1168–1171
41. Berggren Soderlund M, Fex G, Nilsson-Ehle P (2003) Decreasing
serum concentrations of all-trans, 13-cis retinoic acids and retinol
during fasting and caloric restriction. J Intern Med 253:375–380
42. Janke J, Engeli S, Boschmann M et al (2006) Retinol-binding
protein 4 in human obesity. Diabetes 55:2805–2810
43. Dubuc GR, Phinney SD, Stern JS, Havel PJ (1998) Changes of
serum leptin and endocrine and metabolic parameters after
7 days of energy restriction in men and women. Metabolism
47:429–434
44. Vitkova M, Klimcakova E, Kovacikova M et al (2007) Plasma
levels and adipose tissue messenger ribonucleic acid expression
of retinol-binding protein 4 are reduced during calorie restric-
tion in obese subjects but are not related to diet-induced
changes in insulin sensitivity. J Clin Endocrinol Metab
92:2330–2335
45. Shetty PS, Watrasiewicz KE, Jung RT, James WP (1979) Rapid-
turnover transport proteins: an index of subclinical protein-energy
malnutrition. Lancet 2:230–232
46. Tsutsumi C, Okuno M, Tannous L et al (1992) Retinoids and
retinoid-binding protein expression in rat adipocytes. J Biol Chem
267:1805–1810
47. Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin
stimulates glucose utilization and fatty-acid oxidation by activat-
ing AMP-activated protein kinase. Nat Med 8:1288–1295
Diabetologia (2008) 51:1901–1911 1911
